Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 2

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 2
---
333-275409) of which this proxy statement/prospectus forms a part (as amended, the “Registration Statement”). The Registration Statement was initially declared effective by the SEC on August 9, 2024. On August 16, 2024, Liminatus Pharma, LLC (“Liminatus”) informed us that Targeted Diagnostics & Therapeutics, Inc. (“TDT”), Liminatus’s license partner for the intellectual property and other rights related to GCC (CAR-T therapy and cancer vaccine), terminated the License and Development Agreement, dated June 10, 2018, by and between TDT and Liminatus (the “TDT License Termination”). TDT asserted that the termination was due to Liminatus’ failure to make the milestone payments under the agreement, but Liminatus believes it was current on the milestone payments. TDT has not communicated further since terminating the license. Following the receipt of the termination notice, and after considering the development status of the CAR-T products, Liminatus management concluded, in its business judgment, that notwithstanding the loss of the license from TDT and considering the pre-clinical advancement and market potential of its CD47 asset, to proceed with its business plan without the license from TDT.

This Post-Effective Amendment No. 3 (the “Amendment”) to the Registration Statement is being filed by ParentCo to update the Registration Statement to: (i) include the information contained in Iris Acquisition Corp’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 27, 2024, and the financial information of Liminatus as of and for the period ended September 30, 2024, (ii) update the unaudited pro forma combined financial information contained in the Registration Statement, (iii) update information regarding the business of Liminatus, following the TDT License Termination, (iv) update the total merger consideration to be received by securityholders of Liminatus upon the consummation of the Business Combination referred to in the Registration Statement, following the TDT License Termination, and (v) update certain other information in the Registration Statement.

The information included in this filing amends the Registration Statement and the proxy statement/ prospectus contained therein. No additional securities are being registered under this Amendment. All applicable registration fees were paid at the time of the original filing of the Registration Statement.

TABLE OF CONTENTS

**The information in this proxy